Brizzi Marisa, Pérez Sarah E, Michienzi Sarah M, Badowski Melissa E
University of Cincinnati Health, Cincinnati, OH, USA.
Ruth M. Rothstein CORE Center, Cook County Health, Chicago, IL, USA.
Ther Adv Infect Dis. 2023 Jan 31;10:20499361221149773. doi: 10.1177/20499361221149773. eCollection 2023 Jan-Dec.
The treatment of human immunodeficiency virus (HIV) has greatly advanced over the past few decades from complex regimens, with high toxicities, multiple daily dosing, and incomplete viral suppression to more simplified, highly effective, daily oral regimens. Although these advancements greatly improved access and tolerability, the need for daily antiretroviral (ARV) administration remained until recently. With long-acting (LA) injectable ARV options emerging, patients may choose how they want to receive treatment. By eliminating the barrier of daily medication adherence, LA injectable ARV formulations have the potential to not only improve health outcomes for the individual, but also the community by reducing HIV transmission. At the time of this writing cabotegravir/rilpivirine (LA-CAB/RPV) is the only LA injectable ARV regimen approved as a complete regimen for the treatment of HIV in adults and adolescents (⩾35 kg and ⩾12 years of age) who are virologically suppressed. However, additional studies of LA-CAB/RPV in expanded populations, and of other LA ARVs, are underway. The goal of this article was to summarize clinical data and review pertinent clinical considerations for the use of LA-CAB/RPV in the management of HIV.
在过去几十年里，人类免疫缺陷病毒（HIV）的治疗取得了巨大进展，从毒性高、每日多次给药且病毒抑制不完全的复杂治疗方案，发展到更简化、高效的每日口服治疗方案。尽管这些进展极大地改善了治疗的可及性和耐受性，但直到最近，每日抗逆转录病毒（ARV）治疗的需求仍然存在。随着长效（LA）注射用抗逆转录病毒药物的出现，患者可以选择他们希望接受治疗的方式。通过消除每日服药依从性的障碍，长效注射用抗逆转录病毒药物制剂不仅有可能改善个体的健康状况，还能通过减少HIV传播改善社区的健康状况。在撰写本文时，卡博特韦/利匹韦林（LA-CAB/RPV）是唯一被批准作为完整治疗方案用于治疗病毒学抑制的成人和青少年（体重≥35 kg且年龄≥12岁）HIV的长效注射用抗逆转录病毒治疗方案。然而，正在对LA-CAB/RPV在更广泛人群以及其他长效抗逆转录病毒药物方面开展更多研究。本文的目的是总结临床数据，并回顾在HIV管理中使用LA-CAB/RPV的相关临床注意事项。
